

Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair

Agata Smogorzewska,^{1,2,6} Shuhei Matsuoka,^{1,6} Patrizia Vinciguerra,³ E. Robert McDonald, III,¹ Kristen E. Hurov,¹ Ji Luo,¹ Bryan A. Ballif,⁴ Steven P. Gygi,⁴ Kay Hofmann,⁵ Alan D. D'Andrea,³ and Stephen J. Elledge^{1,*}

¹ Department of Genetics, Howard Hughes Medical Institute, Center for Genetics and Genomics, Room 158D, 77 Avenue Louis Pasteur, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

² Department of Pathology, Massachusetts General Hospital, Boston, MA 02214, USA

³ Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

⁴ Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA

⁵ Miltenyi Biotec GmbH, 50829 Koeln, Germany

⁶ These authors contributed equally to this work.

*Correspondence: selledge@genetics.med.harvard.edu

DOI 10.1016/j.cell.2007.03.009

SUMMARY

Fanconi anemia (FA) is a developmental and cancer-predisposition syndrome caused by mutations in genes controlling DNA interstrand crosslink repair. Several FA proteins form a ubiquitin ligase that controls monoubiquitination of the FANCD2 protein in an ATR-dependent manner. Here we describe the FA protein FANCI, identified as an ATM/ATR kinase substrate required for resistance to mitomycin C. FANCI shares sequence similarity with FANCD2, likely evolving from a common ancestral gene. The FANCI protein associates with FANCD2 and, together, as the FANCI-FANCD2 (ID) complex, localize to chromatin in response to DNA damage. Like FANCD2, FANCI is monoubiquitinated and unexpectedly, ubiquitination of each protein is important for the maintenance of ubiquitin on the other, indicating the existence of a dual ubiquitin-locking mechanism required for ID complex function. Mutation in *FANCI* is responsible for loss of a functional FA pathway in a patient with Fanconi anemia complementation group I.

INTRODUCTION

The ability to sense and respond to DNA damage and DNA replication stress is critical for cellular and organismal survival. A failure to properly respond to genotoxic stress can lead to both developmental difficulties and tumorigenesis. Cells have evolved a complex signal transduction pathway that senses genotoxic stress and responds by activating

specific types of repair, arresting the cell cycle and altering transcription. At the core of this signal transduction pathway are the ATM and ATR kinases (Bakkenist and Kastan, 2004; Bartek et al., 2004; Zhou and Elledge, 2000). These kinases phosphorylate over 20 known proteins in response to damage, including the Chk1 and Chk2 kinases. While early theories on these pathways considered their major role to be controlling cell cycle transitions, it is now clear that they play critical roles in regulating essential functions in both DNA replication and DNA repair.

One pathway regulated by ATM/ATR is the Fanconi anemia (FA) crosslink repair pathway (Gurtan and D'Andrea, 2006). Patients with FA display multiorgan defects, and most develop bone marrow failure in childhood (Butturini et al., 1994; Fanconi, 1967; Schmid and Fanconi, 1978). FA patients have a high incidence of hematological and nonhematological malignancies, and their cells are hypersensitive to DNA interstrand crosslinking agents such as mitomycin C (MMC) (Alter et al., 2003). FA falls into 13 complementation groups, and 12 FA genes have been cloned (Gurtan and D'Andrea, 2006; Reid et al., 2007; Taniguchi and D'Andrea, 2006; Xia et al., 2006, 2007). Eight of these proteins (all but D2, D1, J, and N) are subunits of an FA core complex, a nuclear E3 ubiquitin ligase (Machida et al., 2006; Meetei et al., 2004). A key substrate of this ligase is FANCD2, which is monoubiquitinated on lysine 561 (Garcia-Higuera et al., 2001). It has been hypothesized that there is another critical substrate for the ligase in addition to FANCD2, because fusion of ubiquitin to the chicken FANCD2 protein mutant for the lysine acceptor allows complementation of chicken FANCD2 mutants but not FA mutants defective for the ligase activity (Matsushita et al., 2005).

FANCD2 ubiquitination is critical for MMC resistance and is required for the FANCD2 protein to form damage-induced foci on chromatin (Garcia-Higuera et al., 2001). How the FA pathway controls interstrand crosslink repair

is not clear, but an important finding was that the *FANCD1* gene is BRCA2, which has a known role in regulation of Rad51-loading and homologous recombination (HR) (Howlett et al., 2002).

Of all of the FA complementation groups, only FA-I remains uncharacterized at the molecular level (Levitus et al., 2004). FA-I mutant cells do not ubiquitinate FANCD2, precluding its localization to repair foci. Like FA-D2 cells, FA-I cell lines have normal FA E3 ligase complex formation (Levitus et al., 2004).

ATR appears to directly regulate the FA pathway. ATR is required for monoubiquitination of FANCD2 (Andreassen et al., 2004) and phosphorylates FANCD2 on several sites required for FANCD2 function (Ho et al., 2006; Taniguchi et al., 2002). In this study we provide new data supporting a role for DNA-damage signaling in the FA pathway. Through a proteomic screen for substrates for the ATM and ATR kinases (S. Matsuoka et al., submitted) combined with a DNA-damage sensitivity screen, we identified the *FANCI* gene, which is mutated in FA-I cells. FANCI is paralogous with FANCD2, is also monoubiquitinated on a lysine critical for its function, and may be the second critical FA ligase substrate. FANCI binds FANCD2 to form the ID complex that loads onto chromatin in response to DNA damage.

RESULTS

KIAA1794/FANCI Is a Phosphoprotein

KIAA1794/FANCI was identified as a protein whose phosphorylation was induced upon ionizing radiation (IR) treatment (S. Matsuoka et al., submitted). In that study, SILAC (reviewed in Mann [2006]) and peptide immunoprecipitation (Rush et al., 2005) using phosphospecific antibodies followed by mass spectrometry before and after DNA damage was used to identify those proteins that were inducibly phosphorylated on SQ or TQ motifs. Three phosphorylation sites were detected in a human KIAA1794 protein: S730, T952, S1121, and two other sites in the mouse protein S555, T558. We renamed the KIAA1794 protein as FANCI since, as shown below, the locus encoding this protein is mutated in an individual with Fanconi anemia complementation group I. Immunoblotting of FANCI after IR with a phospho-SQ antibody confirmed its inducible phosphorylation (Figure 1A), thus placing it in the ATM/ATR pathway.

Multicolor Competition Assay (MCA)

To efficiently study DNA-damage sensitivity of cells with a variety of genetic perturbations, we developed a simple competition assay that is both quantitative and fast (Figure 1B). Two populations of U2OS (osteosarcoma) cells differing only in their color were created by expression of red (RFP) or green (GFP) fluorescence protein. siRNA depletion of the protein of interest was carried out in the green cells, while the red cells were transfected with control siRNA. Equal numbers of green and red cells were mixed, left untreated, or treated with gamma irradiation or MMC.

After 7 days, cells were harvested and ratio of red-to-green cells determined using flow cytometry. The green-to-red ratio in untreated cells acted as a control for the relative cell growth. The assay was validated using siRNAs targeting ATM (IR sensitivity) and ATR (MMC and IR sensitivity) (Figures 1C and S1).

MCA was applied to study a subset of ATM and ATR substrates (S. Matsuoka et al., submitted). Cells treated with a combination of three siRNAs against one of the tested proteins, FANCI (KIAA1794, a.k.a. FLJ10719), demonstrated 60% survival after 70 nM MMC treatment and 91% survival after 3Gy IR treatment relative to control siRNA-transfected cells (data not shown). To exclude off-target effects, three siRNAs were tested independently. Two of three siRNAs reproduced the phenotype of MMC sensitivity with only a slight effect on the IR sensitivity (Figure 1C). This decreased survival is due to a DNA repair defect as metaphase spreads of primary fibroblasts transfected with FANCI siRNA and treated with MMC revealed frequent cytogenetic abnormalities including chromatid and chromosome breaks as well as radial forms (Figure 1D), hallmarks of Fanconi anemia.

FANCI Displays Homology to FANCD2

BLAST analysis with FANCI revealed high conservation among eukaryotes from human to *Dictyostelium* but not yeasts and limited conservation to a predicted partial *S.purpuratus* sequence similar to FANCD2 (Figure 2A). The homology region extended over 151 amino acids with 19% identity and 45% similarity. The coding region of *FANCI* was amplified from a human lymphocyte cDNA library (Elledge et al., 1991) and recovered an open reading frame of 3984 nucleotides, coding for a 1328 aa protein of a calculated molecular weight 150 kDa. This cDNA corresponds to a putative splice variant isoform 3 of the KIAA1794 (Q9NV11) locus on chromosome 15q25-q26.

Alignment of FANCI and FANCD2 revealed a modest 13% identity and 20% similarity across the entire protein (Figures 2B and S3). Comparable levels of similarity were found between the FANCD2 and FANCI paralogs in other species including *A. thaliana* and *D. melanogaster*. The most striking conservation between FANCI and FANCD2 throughout species surrounded K523 in FANCI and K561 in FANCD2 (Figures 2B and 2C). This site has been previously shown to be monoubiquitinated in FANCD2 and to be essential for the functionality of the FA pathway (Garcia-Higuera et al., 2001).

FANCI Participates in Cell-Cycle Checkpoints and DNA Repair Pathways

As the ATM/ATR pathways control multiple cellular responses, we asked if FANCI participates in cell-cycle control, DNA synthesis control, or HR following DNA damage. siRNA against FANCI abrogated the G2/M checkpoint in U2OS cells (Figure 3A) and also had a small but reproducible effect in the intra-S phase checkpoint (Figure 3B). Interestingly, in unirradiated cells FANCI depletion caused an increased basal level of damage as




Figure 1. Identification of the KIAA1794/FANCI Protein

(A) Western analysis with an antibody raised against a phosphorylated form of SMC3 (SMC3 pS1083) on immunoprecipitates performed with FANCI antibody (BL999) from 293T extracts before and after DNA damage.

(B) Schematic of the multicolor competition assay (MCA). See text for details. In this example, the knockdown of a protein of interest caused the green fluorescent protein (GFP) cells to become DNA-damage sensitive without influencing their proliferative capacity in the absence of damage. The relative resistance to damage of the si-treated cells is 40% of the non-si-treated cells.

(C) MCA analysis in U2OS cells treated with siRNAs against ATM and ATR and three different siRNAs against FANCI.

(D) Cytogenetic abnormalities in IMR90 cells transfected with siRNA against *FANCI* or LacZ control and treated with 0, 5, or 7.5 ng MMC per ml. Asterisk indicates a statistically significant difference in means as calculated by the t test. Experiment with 7.5 ng MMC per ml was performed once.

judged by γ -H2AX (Figure 3C) indicative of a role in maintenance of genomic stability.

The FA pathway has been previously implicated in HR (Nakanishi et al., 2005; Niedzwiedz et al., 2004; Yamamoto et al., 2005), and therefore we examined FANCI for a potential role in HR repair. DR-U2OS cells used in this assay (Xia et al., 2006) have an integrated HR reporter. Induction of a double-strand break, resulted in a robust repair as indicated by the appearance of 12% GFP-positive cells (Figure 3D). All four siRNAs to FANCI reduced recombination from 78% to 47% of controls, similar to siRNAs to ATR, FANCA, and FANCD2 (Nakanishi et al., 2005) but less than siRNAs to BRCA1 and BRCA2, which are thought to be more directly involved in the recombination process (Figures 3E and 3F). These results indicate that FANCI is an important component of the HR-repair pathway.

FANCI Localizes to Damage-Induced Foci in Multiple Cell Types

To assess FANCI localization, immunofluorescence experiments were performed on transformed (U2OS, HeLa,

and 293T) and primary (BJ) cell lines. Analysis using two antibodies BL999 and BL1000 revealed foci in a subset of untreated cells and in nearly all cells after DNA damage. In some experiments, a nuclear rim staining was also detected. These FANCI foci corresponded to damage-induced foci as they colocalize with FANCD2 staining (Figure 4A) (Garcia-Higuera et al., 2001). Confirmation of the antibody specificity was achieved using transfected Myc-FANCI and anti-Myc antibodies (Figure S4A). siRNA-treated cells showed decreased damage-induced foci staining with BL999 and BL1000 antibodies after Triton-X pre-extraction (data not shown).

FANCI and FANCD2 Form a Complex Required for FANCD2 Localization to Damage-Induced Foci

Depletion of FANCI in U2OS using three separate siRNAs resulted in diminished ubiquitination of FANCD2 upon damage (Figure 4C), and the loss of this modification corresponded to a prominent reduction in FANCD2 signal at damage-induced foci as well as appearance of cells with no visible FANCD2 foci (Figure 4B). Moreover, the




Figure 3. Checkpoint and Repair Defects in Cells with Reduced Levels of FANCI

(A) Cells depleted for FANCI have checkpoint defects. U2OS cells were treated as shown in the schematic. Two separate fields of cells were examined. The mean and standard deviation from two fields are shown. Average of 1000 cells per siRNA were scored.

(B) Effects of FANCI depletion on radioresistant DNA synthesis. U2OS cells transfected with the indicated combination of three different siRNAs were irradiated with 5Gy or 10Gy of IR depending on an experiment, allowed to recover for 30 minutes and assayed in triplicate for DNA synthesis. The means and standard deviations of four separate experiments are shown. For comparison, IR treatment of the ATM siRNA-transfected cells causes DNA synthesis to be 70%–80% of the level found in the untreated cells.

(C) Reduction of FANCI causes spontaneous DNA damage. U2OS cells transfected with the indicated combinations of three different siRNAs were collected 3 days later, and the level of γ -H2AX was assayed without inflicting any exogenous damage. Western analysis with Ran antibody acted as a loading control.

(D) Flow cytometric analysis of DR U2OS cells uninfected or infected with the AdNgus24i adenovirus carrying I-SceI (I-SceI-Ad) or AdCA36 carrying β -galactosidase (β -gal-Ad). Infections were carried out at a multiplicity of infection of 5, and analysis for GFP-positive cells was performed at 36 hrs after infection.

(E and F) FANCI is required for HR. In (E), DR U2OS cells were transfected with the indicated combination of three different siRNAs and 3 days later were infected with 10 pfu/cell of adenovirus carrying I-SceI. Flow cytometric analysis of GFP-positive cells was carried out 36 hrs after infection. Mean and standard deviation of eight experiments (ATM), seven experiments (ATR), four experiments (Brca2), and three experiments (FANCI) are shown. In (F), DR U2OS cells were transfected with the indicated RNAs, infected with 5 pfu/cell of adenovirus carrying I-SceI (AdNgus24i) and analyzed 24 hrs later.

FANCI appeared ubiquitinated. Since the experiment was done in the absence of exogenous damage, we conclude that endogenous FANCI is modified in an unperturbed S phase.

Ubiquitination of FANCI Is FANCA and FANCD2 dependent

To search for the E3 ubiquitin ligase for FANCI, we examined FANCI modification in FANCA mutants defective for




Figure 4. FANCI Localizes and Interacts with FANCD2

(A) Localization of the endogenous FANCI using BL999 and BL1000 antibodies. U2OS cells treated with 1 μ M MMC for 24 hr were Triton-X-extracted before costaining with anti-FANCI (BL999 or BL1000) and anti-FANCD2 antibodies.

(B) Localization of FANCD2 in cells transfected with individual siRNAs against *FANCI*. U2OS cells were transfected with the indicated individual siRNAs against *FANCI* and treated with 1 μ M MMC. Twenty-four hours later, following Triton-X extraction, the cells were costained with an antibody against FANCD2 and H2AX.

(C) Western analysis of FANCD2 in U2OS cells transfected with individual siRNAs against *FANCI*. L is the long (monoubiquitinated) and S is the short form of the proteins. Asterisk indicates crossreacting band.

(D) Interaction of FANCD2 and FANCI. Total protein (0.5 mg) from PD20 fibroblasts expressing indicated constructs was immunoprecipitated with FLAG or control Myc antibodies under nondamaged conditions. The immunoprecipitates were analyzed by western blotting with a rabbit anti-FANCD2 or mouse anti-HA antibody.

the core E3 ligase complex. FA-A cells GM6914 cells lacking FANCA showed no ubiquitination of the endogenous or HA-tagged FANCI (Figure 5F; lanes 1, 2, 5, and 6), but ubiquitination was restored after complementation with wt FANCA (Figure 5F; lanes 3, 4, 7, and 8).

FANCD2 and FANCI show reciprocal ubiquitination dependencies. PD20 fibroblasts, which lack FANCD2 (Jakobs et al., 1996), when transfected with the ubiquitination-defective FANCD2 K561R mutant also fail to ubiquitinate FANCI (Figure 5G, lanes 3 and 4). The same cells complemented with wt FANCD2 restore FANCI modification (Figure 5G, lanes 5 and 6). PD20 cells expressing wt or K561R FANCD2 also showed increased levels of FANCI (Figure 5G), consistent with the notion that the nonubiquitinated forms of the proteins bind constitutively in a heterodimeric (or multimeric) Fanconi anemia ID complex.

USP1 is the deubiquitinating enzyme for FANCD2 (Nijman et al., 2005). To test whether USP1 also can affect FANCI monoubiquitination, HeLa cells were transfected with siRNA against USP1. Reduction of USP1 increased the

L to S ratio for both FANCI and FANCD2 under basal conditions and after HU treatment (Figure 5H).

Lysine 523 of FANCI Is Critical for Its Ubiquitination

To determine whether the conserved lysine 523 of FANCI was required for ubiquitination, a wt or K523R mutant HA-tagged FANCI were stably expressed in GM6914 (Figure 5F) and in 293T cells (Figure S5A). Only in cells that expressed the wt FANCI but not the K523R mutant was the L form detected with the HA antibody (Figures 5F [lanes 7, 8, 11, and 12] and S5A). Interestingly, cells overexpressing the FANCI K523R mutant, but not wt, showed diminished monoubiquitination of FANCD2 (Figures 5F [lanes 11 and 12] and S5A), suggesting that the mutant FANCI displays a dominant-negative activity.

Consistent with the role of FANCI in ubiquitination of FANCD2, the FANCI K523R mutant failed to form DNA damage foci (Figure 5I; + Triton) despite its overproduction (data not shown). Cells expressing K523R FANCI allele showed pan-nucleoplasmic FANCD2 staining and




Figure 5. FANCI Ubiquitination and Its Dependence on Fanconi Anemia Pathway

(A) Western blot analysis of FANCI in U2OS cells. U2OS cells were treated with 1 μ M MMC, and 24 hr later, cells were lysed directly in 2 \times Laemmli buffer. Long (L) and short (S) forms of FANCI are shown. The asterisk indicates a crossreacting band.

(B) In vivo ubiquitination of FANCI. Whole cell extracts of 293T cells transiently transfected with HA-tagged ubiquitin or control plasmid carrying dsRed marker were immunoprecipitated using antibodies raised against FANCI and analyzed by western blot with a FANCI antibody (left) and antibody recognizing the HA tag (right).

(C) In vivo ubiquitination of FANCI. HeLa cells expressing ubiquitin tagged with His and a biotinylation signal were treated with 2 mM HU for 16 hrs, lysed in 8 M urea, and precipitated using Streptavidin beads under denaturing conditions.

(D) Chromatin fractionation of FANCI in U2OS cells. Cells were treated with 1 μ M MMC and 24 hrs later cells were collected and processed into cellular fractions. Whole cell extract (WCE), cytoplasmic proteins (S1), intact nuclei (P1), soluble nuclear proteins (S2), chromatin-enriched pellet (P2), and soluble and insoluble fractions after micrococcal nuclease treatment (S2' and P2') are indicated. Orc2 antibody was used to follow the chromatin fraction.

(E) Cell-cycle analysis of FANCI ubiquitination. After release from nocodazole, cells were collected at indicated times for the western analysis (top panel) and for cell-cycle analysis using flow cytometry (lower panel).

(F) Analysis of ubiquitination in GM6914 (FA-A) fibroblasts. Cells expressing vector or wt FANCA were stably transduced with empty vector, or HA-tagged wt FANCI. Twenty-four hours after 1 μ M MMC treatment cells were collected, and western blotting was performed with the indicated antibodies.

(G) Analysis of ubiquitination in PD20 (FA-D2) fibroblasts. Cells expressing vector, K561R mutant, or wt FANCD2 were treated with 2 mM HU and collected 15 hrs later. Western blotting was performed with the indicated antibodies, including FANCD2 antibody to confirm absence (lanes 1 and 2) or presence (lanes 3, 4, 5, and 6) of FANCD2 protein. The asterisk indicates a crossreacting band.

(H) Ubiquitination of FANCD2 and FANCI in HeLa cells transfected with siRNA against USP1 and lacZ control, treated with 2 mM HU, and collected 15 hrs later. L/S indicates the ratio of the monoubiquitinated to nonubiquitinated FANCI or FANCD2.

(I) Localization of FANCI and FANCD2 in wt and K523R FANCI-expressing U2OS cells. Cells stably transduced with the HA-tagged wt or K523R mutant allele of FANCI were treated with 1 μ M MMC and processed 24 hrs later for immunofluorescence. Note that cells not expressing K523R in the lower panels (K523R – Triton) are included as controls for FANCD2 staining. Two FANCD2-positive cells in the lower right panel (+ Triton) are presumed not to have K523R FANCI expression, although that cannot be tested directly since Triton-X removes nucleoplasmic FANCI. Similar results were observed in U2OS cells expressing the K523R mutant treated with HU.

greatly diminished localization to DNA damage-induced foci best visualized after Triton-X pre-extraction (Figure 5I). These data show that the K523R mutant has a dominant-negative effect on FANCD2 foci formation.

FANCI Is Mutated in Cells from the Fanconi Anemia Complementation Group I

Phenotypic similarities of cells with reduced levels of FANCI to cells from Fanconi anemia patients, including marked MMC but only mild IR sensitivity (Figure 1B), alerted us to the possibility that mutations in *FANCI* might be responsible for human disease. Published reports included only one remaining complementation group for which the responsible gene was unknown, Fanconi anemia complementation group I (Levitus et al., 2004). We worked with one of the cell lines from this group, BD0952, Epstein Barr Virus-transformed peripheral lymphocytes from a patient with a classic presentation of Fanconi anemia. BD0952 express a full-length FANCI protein at normal levels relative to control cells (GM03288) (Figure 6A). However, this protein is not ubiquitinated in BD0952 cells, even after MMC treatment (Figure 6A and data not shown).

FANCD2 is not ubiquitinated in FA-I cells (Figure 6A) (Levitus et al., 2004), thus restoration of FANCD2 ubiquitination acts as a surrogate marker for the functional complementation of the Fanconi anemia pathway. Expression of the FANCI cDNA in BD0952 cells restored FANCD2 ubiquitination (Figure 6A). This exogenous FANCI was also monoubiquitinated (Figures 6A and S5B). Appearance of the monoubiquitination was not due to changes in the cell cycle of the cells expressing FANCI (Figure S5C). Also, the levels of expression of the exogenous proteins were comparable to the endogenous protein (compare tagged [T] versus endogenous [E], Figures 6A and Figure S5B). Expression of wt FANCI in BD0952 also complemented their MMC resistance to wt levels (Figure 6B).

To look for *FANCI* mutations in BD0952 cells, we amplified and sequenced the cDNA from BD0952 mRNA and found two base substitutions as candidates for the Fanconi anemia-causing mutation in BD0952 cells. They included a C to T transition, which resulted in Pro to Leu change at amino acid 55, and a G to A transversion, which resulted in Arg to Gln substitution in an absolutely conserved Arg1285 at the C terminus of the protein. We confirmed these mutations by amplifying exon 3 and exon 36 from genomic DNA. Sequencing confirmed presence of both mutations in genomic DNA in homozygous form (Figure 6C). Homozygosity was expected at the disease locus since the patient comes from a consanguineous family with both parents expected to contribute the disease allele of *FANCI* to their child.

To test which mutation causes the disease, we made expression constructs containing P55L, R1285Q, and P55L-R1285Q substitutions. Only the wt and the P55L allele were able to complement the FANCD2 monoubiquitination defect (Figure 6D) and MMC sensitivity (Figure 6E) of BD0952 cells. These two proteins were also themselves

monoubiquitinated in BD0952 cells. When introduced into U2OS cells or into BD0952 cells, the P55L allele was found in foci together with FANCD2 (Figures 7A and S6). Cells expressing R1285Q or P55L-R1285Q alleles showed no monoubiquitination of FANCD2 (Figure 6D) and failed to restore MMC resistance (Figure 6E). Unlike wt FANCI allele, which could complement breakage phenotype seen in BD0952 cells, the R1285Q allele-expressing cells showed a high number of aberrations after treatment with MMC (Figure 6F). When introduced into U2OS or BD0952 cells, the R1285Q or P55L-R1285Q alleles failed to localize to damage-induced foci (Figures 7A [+ Triton panel] and S6) despite robust expression levels of the mutant proteins as judged by the immunofluorescence staining in the absence of triton extraction (Figure 7A; – Triton panel). Together, these studies indicate that the R1285Q change is the disease-causing mutation in BD0952 cells.

Unexpectedly, we found the K523R FANCI allele was able to partially complement the FANCD2 monoubiquitination defect (Figure 6A; lanes 7 and 8) and MMC sensitivity defect in BD0952 cells (Figure 6F). This is in contrast to the findings that FANCI K523R mutant fails to be ubiquitinated or form damage-induced foci and that K523R allele when overexpressed acts as a dominant negative against FANCD2 ubiquitination and foci formation. These results suggest either that this allele is only partially defective or more likely that it is displaying interallelic complementation with the FANCI R1285Q mutant present in BD0952 cells. Further studies will be needed to resolve this issue.

DISCUSSION

The response to DNA damage and DNA replication stress is orchestrated by the ATM and ATR kinases that direct the phosphorylation of key proteins that carry out this stress response. Knowledge of their substrates is key to both identifying and elucidating DNA repair responses. In this study we examine one such recently identified substrate of these kinases (S. Matsuoka et al, submitted), the KIAA1794 protein, which we discovered to be encoded by the *FANCI* gene.

FANCI Is a FANCD2 Paralog Required for Crosslink Repair

FANCI depletion caused a phenotype consistent with a role in DNA crosslink repair. FANCI is highly conserved from humans to *Dictyostelium*, but absent in budding and fission yeast. The interior of FANCI, like that of FANCD2, is composed of ARM repeats that fold into superhelical helices, suggesting that these proteins have an extended structure. A crucial finding was a short stretch of similarity to Sea Urchin FANCD2, a central component of the Fanconi anemia pathway. This conserved region contained a key lysine known to be monoubiquitinated in FANCD2 that is critical for FANCD2 function. FANCI contains a weak but significant similarity throughout the length of the human FANCD2 protein. As FANCI and FANCD2 are approximately the same size, show




Figure 6. Complementation of BD0952 (FA-I) Cells with the KIAA1794/FANCI cDNA

(A) Complementation of FANCD2 ubiquitination defects in FA-I cells by expression of wt FANCI. Cells stably transduced with empty vector, HA-tagged wt, or K523R FANCI were untreated or treated with 100 nM MMC and collected 24 hrs later by lysis in Laemmli buffer. Western analysis with FANCD2, FANCI, and HA antibodies was performed. GM02188 (wt control) cells acted as a control for the presence of long (L, ubiquitinated) forms of FANCD2 and FANCI, which are absent in the uncomplemented BD0952 cells. The transduced form of the protein is identified as T (tagged), since it runs slightly slower than the endogenous (E) form. Also see Figure S5B.

(B) Complementation of MMC sensitivity of BD0952 cells by expression of wt FANCI but not empty vector. Logarithmically growing cells of indicated genotypes were treated in triplicate with different levels of MMC ranging from 0 to 100 nM. They were allowed to grow for 6 days, at which time they were harvested, and total cell number was counted using a coulter counter. Total cell numbers at each dose were divided by the number of cells in the untreated sample to arrive at percent survival.

(C) Sequence analysis of the FANCI genomic locus in BD0952 (FA-I) cells. Sequence of the genomic contig (ref|NT_010274.16|Hs15_10431:4714523-4889523 Homo sapiens chromosome 15 genomic contig, reference assembly) and sequence traces of genomic DNA from BD0952 cells are shown together with the resulting amino acid sequence deduced from the DNA sequence data.

(D) Complementation of FANCD2 ubiquitination by expression of wt FANCI or P55L FANCI, but not R1285Q or P55L-R1285Q FANCI mutants. Cells stably transduced with the indicated alleles of FANCI were left untreated or were treated with 100 nM of MMC and processed 24 hrs later as indicated in (A).

(E) Complementation of MMC sensitivity of BD0952 cells by expression of WT FANCI or P55L FANCI, but not R1285Q or P55L-R1285Q FANCI mutants. Experiments were done as indicated in (B). MMC treatments were done in triplicate and the mean and standard deviation is shown.

(F) Cytogenetic abnormalities in BD0952 cells expressing wt, K523R, or R1285Q FANCI alleles. Indicated cells were treated with 0, 20, or 40 ng MMC per ml of media and analyzed for presence of chromosomal aberrations 48 hrs later. K523R mutant was not assessed at 20 ng of MMC per ml. Analysis was done only once at 40 ng of MMC per ml. Thirty to fifty metaphases were evaluated for each cell line.

similarity along their length, and both have an extended region of superhelical ARM repeats, it is likely that these proteins were derived from a common ancestral gene duplication event and subsequently diverged through evolution to produce two functionally distinct paralogs.

FANCI Is Mutated in FA-I Cells

As KIAA1794/FANCI showed characteristics of a Fanconi anemia protein we anticipated that previously unassigned Fanconi patients might harbor mutations in our gene. We were able to obtain BD0952 cells from the FA-I




Figure 7. Localization of Mutant FANCI Alleles

(A) Localization of wt, P55L, R1285Q, and P55L-R1285Q mutant proteins in U2OS cells. U2OS cells transduced with the indicated alleles of *FANCI* were treated with 100 nM MMC, and 24 hrs later, were processed for immunofluorescence.

(B) Model of Fanconi anemia ID complex regulation and function. The phosphorylation-ubiquitination cascade culminates in chromatin loading of the Fanconi anemia ID complex, which directs downstream repair events.

complementation group. FA-I cells are MMC sensitive and fail to monoubiquitinate FANCD2 or form FANCD2 foci in response to DNA damage. Retrovirally expressed FANCI complemented FA-I mutants for all three phenotypes. DNA-sequence analysis revealed two amino acid changes in the FANCI protein. Complementation analysis reveals that the R1285Q mutation is responsible for the defect in BD0952 cells and fails to restore MMC resistance and FANCD2 regulation. The R1285Q mutation is present in both copies of FANCI in these cells consistent with family consanguinity. The complementation, coupled with the identification of inactivating mutations in BD0952 cells, unambiguously identifies KIAA1794 as the *FANCI* gene. Preliminary analysis revealed a candidate causative mutation, C3853T, in a second FA-I cell line, EUFA816, resulting in conversion of the essential R1285 to a stop codon (A.S. and S.J.E., unpublished data), further highlighting the importance of the C terminus of FANCI for its function. FANCI in the other FA-I cell lines (Levitus et al., 2004) remains to be examined for the presence of mutations to confirm the cell-fusion data that placed them in the same complementation group as BD0952 cells.

FANCI Is Monoubiquitinated

Like FANCD2, FANCI has a slower migrating form that several lines of evidence suggest is due to monoubiquitination. First, the key lysine responsible for FANCD2 ubiquitination is conserved in FANCI. Secondly, FANCA mutant cells defective for the FA ubiquitin ligase complex fail to generate the slower migrating form. Third, mutation of this lysine, K523R, in FANCI prevents formation of the slower migrating form. Finally, FANCI antibodies specifically immunoprecipitate epitope-tagged ubiquitin covalently attached to FANCI. Like FANCD2, the ubiquitinated form of FANCI is enriched on chromatin and the K523R FANCI mutant does not get loaded onto chromatin. The significance of FANCI monoubiquitination is illustrated by the fact that the K523R mutant of FANCI does not itself become monoubiquitinated and does not form damage foci. When introduced into U2OS cells, which express a wt FANCI allele, this mutant reduced FANCD2 monoubiquitination and foci formation. Furthermore, the K523R mutant fails to fully complement FANCD2 ubiquitination or MMC sensitivity of BD0952 cells, indicating that ubiquitination is important for FANCI function. As this line is not

a null mutant, it is possible that this intermediate FANCD2 monoubiquitination and MMC-resistance phenotype might represent interallelic complementation.

FANCI and FANCD2 Form an Interdependent ID Complex that Is Required for Ubiquitination and Chromatin Association

We anticipated that FANCI would associate with FANCD2 because FANCI protein formed foci that colocalized with FANCD2; depletion of FANCI significantly reduced the monoubiquitination of FANCD2, preventing its inclusion into DNA damage-induced foci; and FA-I cells have completely lost their ability to monoubiquitinate FANCD2 despite fully formed FA complex (Levitus et al., 2004). Indeed, FANCI forms a complex with FANCD2, with approximately 20% of FANCD2 coimmunoprecipitating with tagged FANCI protein. The FANCI-FANCD2 complex, which we propose to call the Fanconi anemia ID complex, thus joins the Fanconi anemia core complex as a new downstream complex necessary for interstrand crosslink repair and HR.

Just as the FANCI protein monoubiquitination is required for FANCD2 ubiquitination and foci formation, FANCD2 and FANCD2 ubiquitination are required for FANCI ubiquitination. Thus, these two paralogs are interdependent and employ a dual ubiquitination mechanism to affect downstream effector function. Furthermore, phosphorylation of FANCD2 is required for its own efficient ubiquitination and therefore for the efficient ubiquitination of FANCI. By extension, FANCI phosphorylation is also expected to be an essential event for the FA pathway following DNA damage and during normal S phase progression. This phosphorylation-ubiquitination cascade culminating in chromatin loading of the ID complex offers an exquisite control at sites of stalled forks. The ID complex, when correctly placed, can direct repair pathways to remove the crosslinks and repair the DNA so that replication can resume and cells can survive. Without this key event, cells are prone to genomic instability that can lead to increased cell death, stem cell depletion, and tumorigenesis.

Among the key questions that remain to be answered is how the ID complex is recognized for ubiquitination. Is it directly ubiquitinated by the FANCL ligase complex, or is there a more complex relationship among different ligases converging on this pathway? What is the function of ID ubiquitination, and why must both components be monoubiquitinated? Is it merely required for chromatin loading, or does it direct repair in the same way that proliferating cell nuclear antigen ubiquitination directs repair? Does it represent a ubiquitin code that directs specific repair pathways? The identification of FANCI and the Fanconi anemia ID complex should now allow these issues to be approached with greater clarity.

EXPERIMENTAL PROCEDURES

Cell Lines

Complemented cell lines PD20 and GM6914 were described previously (Taniguchi et al., 2002), and DR-U2OS were provided by

Maria Jasin (Xia et al., 2006). GM02188 was obtained from Coriell, BD0952 from European Collection of Cell Cultures (www.ecacc.org.uk), and U20S from American Cell Culture Collection (ATCC).

Antibodies

Antibodies were as follows: KIAA1794; BL999 and BL1000 (Bethyl); rabbit FANCD2 (Novus); mouse FANCD2 (Santa Cruz); FANCA (Rockland); ORC2 (BD Bioscience); Vinculin (Sigma); HA (Covance); MYC (Covance); SMC3pS1083 (Bethyl); PhosphoH3 (Upstate); Ran (BD Bioscience); γ H2AX (Upstate). For the IPs, we used anti-HA affinity matrix (Roche), anti-FLAG M2 agarose (Sigma), c-MYC (Santa Cruz) and Protein A/G PLUS-Agarose (Santa Cruz). Secondary antibodies for immunofluorescence (IF) were from Molecular Probes and Amersham and for western blots were from Jackson Laboratory.

FANCI Cloning

PCR was performed using Platinum Taq DNA polymerase high fidelity (Invitrogen) on a human cDNA library (Elledge et al., 1991). The total RNA from BD0952 cells was isolated using Trizol (Invitrogen). The RNA was reverse transcribed with Superscript III (Invitrogen) and dT primers. The PCR step was performed using Platinum Pfx DNA polymerase (Invitrogen). Genomic DNA was prepared using DNeasy tissue kit (Qiagen). See [Supplemental Experimental Procedures](#) for primer sequences.

Mutagenesis

The QuikChange II XL site-directed mutagenesis kit (Stratagene) or QuikChange multisite-directed mutagenesis kit (Stratagene) was used to make mutation in FANCI. See [Supplemental Experimental Procedures](#) for primer sequences.

siRNAs

Stealth siRNAs (Invitrogen) were transfected using Oligofectamine (Invitrogen) at a final concentration of 85 nM total siRNAs. Assays were done 48–72 hrs after transfection. Unless indicated otherwise, combination of three siRNAs against the same gene were used. siRNAs used in experiments shown in Figures 1D, 5G, and 5H were purchased from Qiagen. In these experiments, cells were transfected at concentration of 20 nM using Hyperfect according to manufacturer's instructions. See [Supplemental Experimental Procedures](#) for siRNA sequences.

Immunofluorescence

Cells grown on autoclaved cover slips were processed as described in the [Supplemental Experimental Procedures](#). For the IF on lymphoblastic cell lines, coverslips were treated with sterile poly-D-lysine hydrobromide, molecular weight > 300,000 (Sigma), and the cells were allowed to attach for several hours.

Chromatin Fractionation and Immunoprecipitations

Chromatin fractionation was performed as described (Mendez and Stillman, 2000; Zou et al., 2002). Benzoxone (Novagen) was included in immunoprecipitation reactions. Details may be found in [Supplemental Experimental Procedures](#).

MCA

siRNA transfections were performed as described above with green fluorescent protein (GFP) cells being transfected with a control siRNA (luciferase) and red fluorescent proteins (RFP) cells with an siRNA of interest. On day 3 after transfections, GFP and RFP cells were counted and mixed in 1:1 ratio and were left untreated or were treated with IR or MMC. After 7 days of culture, all cells were collected and analyzed using Cytomix FC500 analyzer (Beckman Coulter). Relative survival of Luc siRNA-treated cells after damage was set to 100%.

G2/M Checkpoint Assay

U2OS cells were transfected with individual siRNAs for 3 days in a 96-well format. Cells were irradiated with 5 Gy and allowed to recover for 1 hr before the addition of 100 ng nocodazole per ml of media to trap cells that bypass the G2/M checkpoint. Cells were fixed and stained with an antibody against Phospho-H3 9 hrs after irradiation.

Radioreistant DNA Synthesis Assay

Radioreistant DNA synthesis assays to evaluate the intra-S phase checkpoint were done as described previously (Silverman et al., 2004). For details see Supplemental Experimental Procedures.

HR Assay

HR assay was performed as described (Nakanishi et al., 2005; Xia et al., 2006), except instead of transfecting cells with an I-SceI-expressing plasmid, we used an adenovirus AdNGUS24i (kindly provided by Frank Graham, McMaster University) expressing the I-SceI enzyme. Control adenovirus AdCA36 (Addison et al., 1997) expressed β -galactosidase.

Cell-Cycle Synchronization

U2OS cells were treated with 2.5 mM thymidine for 24 hrs, washed three times and released into 100 ng nocodazole per ml of media, incubated for 12 hrs, and collected by mitotic shakeoff. Cells were washed three times, counted, and plated for collection at different times.

MMC Sensitivity Assay

Logarithmically growing cells were counted and diluted to 2×10^5 cells per ml, plated in triplicate for each drug dose and treated with different concentrations of freshly made MMC. After 6 days in culture, cells were harvested and counted using a Z2 Coulter Counter (Beckman Coulter). Cell numbers in the samples treated with the drug were normalized to the cell numbers in the untreated sample.

Bioinformatics

BLAST was used for homology searches (<http://www.ncbi.nlm.nih.gov/BLAST/>) (Altschul et al., 1997). The SCOP database can be found at <http://scop.mrc-lmb.cam.ac.uk/scop/> (Murzin et al., 1995). Alignments were performed in ClustalX and were rendered using ESPript 2.2 (<http://esprict.ibcp.fr/>) (Gouet et al., 1999).

Supplemental Data

Supplemental Data include six figures and Supplemental Experimental Procedures and can be found with this article online at <http://www.cell.com/cgi/content/full/129/2/289/DC1/>.

ACKNOWLEDGMENTS

We are grateful to K. Nakanishi and M. Jasin for DR U2OS, J. Lin and J.W. Harper for expression constructs, H. Takai and T. de Lange for protocols, F. Graham for the AdNGUS24i and AdCA36 adenoviruses, J. Parvin for His-biotin-Hela, H. Joenje for cell lines, A. Gurtan for reagents, C. Mathew for helpful discussions; A. Brass, M. Schlabach, G. Hu, H. Yen, F. Stegmeier, T. Westbrook, D. Chou, and N. Solimini for constructs and advice; J. Daly and S. Lazo-Kallanian for cell sorting; L. Moreau for the cytogenetic analysis; and A. Liang for technical assistance. A.S. is supported by T32CA09216 to the Pathology Department at the Massachusetts General Hospital. P.V. is a Swiss National Science Foundation Fellow. K.E.H. is a Leukemia and Lymphoma Society Special Fellow. This work was supported by grants from the NIH to S.J.E. and from NIAID 1U19A1067751 to A.D.D. and S.J.E. S.J.E. is a Howard Hughes Medical Institute Investigator.

Received: December 5, 2006
 Revised: February 13, 2007
 Accepted: March 6, 2007
 Published online: April 5, 2007

REFERENCES

- Addison, C.L., Hitt, M., Kunsken, D., and Graham, F.L. (1997). Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. *J. Gen. Virol.* 78, 1653–1661.
- Alter, B.P., Greene, M.H., Velazquez, I., and Rosenberg, P.S. (2003). Cancer in Fanconi anemia. *Blood* 101, 2072.
- Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25, 3389–3402.
- Andreassen, P.R., D'Andrea, A.D., and Taniguchi, T. (2004). ATR couples FANCD2 monoubiquitination to the DNA-damage response. *Genes Dev.* 18, 1958–1963.
- Bakkenist, C.J., and Kastan, M.B. (2004). Initiating cellular stress responses. *Cell* 118, 9–17.
- Bartek, J., Lukas, C., and Lukas, J. (2004). Checking on DNA damage in S phase. *Nat. Rev. Mol. Cell Biol.* 5, 792–804.
- Butturini, A., Gale, R.P., Verlander, P.C., Adler-Brecher, B., Gillio, A.P., and Auerbach, A.D. (1994). Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. *Blood* 84, 1650–1655.
- Elledge, S.J., Mulligan, J.T., Ramer, S.W., Spottswood, M., and Davis, R.W. (1991). Lambda YES: a multifunctional cDNA expression vector for the isolation of genes by complementation of yeast and Escherichia coli mutations. *Proc. Natl. Acad. Sci. USA* 88, 1731–1735.
- Fanconi, G. (1967). Familial constitutional panmyelocytopenia, Fanconi's anemia (F.A.). I. Clinical aspects. *Semin. Hematol.* 4, 233–240.
- Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M.S., Timmers, C., Hejna, J., Grompe, M., and D'Andrea, A.D. (2001). Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Mol. Cell* 7, 249–262.
- Gouet, P., Courcelle, E., Stuart, D.I., and Metoz, F. (1999). ESPript: analysis of multiple sequence alignments in PostScript. *Bioinformatics* 15, 305–308.
- Gurtan, A.M., and D'Andrea, A.D. (2006). Dedicated to the core: understanding the Fanconi anemia complex. *DNA Repair (Amst.)* 5, 1119–1125.
- Ho, G.P., Margossian, S., Taniguchi, T., and D'Andrea, A.D. (2006). Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. *Mol. Cell Biol.* 26, 7005–7015.
- Howlett, N.G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., De Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G., et al. (2002). Biallelic inactivation of BRCA2 in Fanconi anemia. *Science* 297, 606–609.
- Jakobs, P.M., Sahaayaruban, P., Saito, H., Reifsteck, C., Olson, S., Joenje, H., Moses, R.E., and Grompe, M. (1996). Immortalization of four new Fanconi anemia fibroblast cell lines by an improved procedure. *Somat. Cell Mol. Genet.* 22, 151–157.
- Levitus, M., Rooimans, M.A., Steltenpool, J., Cool, N.F., Oostra, A.B., Mathew, C.G., Hoatlin, M.E., Waisfisz, Q., Arwert, F., de Winter, J.P., and Joenje, H. (2004). Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. *Blood* 103, 2498–2503.
- Machida, Y.J., Machida, Y., Chen, Y., Gurtan, A.M., Kupfer, G.M., D'Andrea, A.D., and Dutta, A. (2006). UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. *Mol. Cell* 23, 589–596.
- Mann, M. (2006). Functional and quantitative proteomics using SILAC. *Nat. Rev. Mol. Cell Biol.* 7, 952–958.
- Matsushita, N., Kitao, H., Ishiai, M., Nagashima, N., Hirano, S., Okawa, K., Ohta, T., Yu, D.S., McHugh, P.J., Hickson, I.D., et al. (2005). A

- FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. *Mol. Cell* 19, 841–847.
- Meetei, A.R., Yan, Z., and Wang, W. (2004). FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. *Cell Cycle* 3, 179–181.
- Mendez, J., and Stillman, B. (2000). Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. *Mol. Cell. Biol.* 20, 8602–8612.
- Montes de Oca, R., Andreassen, P.R., Margossian, S.P., Gregory, R.C., Taniguchi, T., Wang, X., Houghtaling, S., Grompe, M., and D'Andrea, A.D. (2005). Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. *Blood* 105, 1003–1009.
- Murzin, A.G., Brenner, S.E., Hubbard, T., and Chothia, C. (1995). SCOP: a structural classification of proteins database for the investigation of sequences and structures. *J. Mol. Biol.* 247, 536–540.
- Nakanishi, K., Yang, Y.G., Pierce, A.J., Taniguchi, T., Digweed, M., D'Andrea, A.D., Wang, Z.Q., and Jasin, M. (2005). Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. *Proc. Natl. Acad. Sci. USA* 102, 1110–1115.
- Niedzwiedz, W., Mosedale, G., Johnson, M., Ong, C.Y., Pace, P., and Patel, K.J. (2004). The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. *Mol. Cell* 15, 607–620.
- Nijman, S.M., Huang, T.T., Dirac, A.M., Brummelkamp, T.R., Kerkhoven, R.M., D'Andrea, A.D., and Bernards, R. (2005). The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. *Mol. Cell* 17, 331–339.
- Reid, S., Schindler, D., Hanenberg, H., Barker, K., Hanks, S., Kalb, R., Neveling, K., Kelly, P., Seal, S., Freund, M., et al. (2007). Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. *Nat. Genet.* 39, 162–164.
- Rush, J., Moritz, A., Lee, K.A., Guo, A., Goss, V.L., Spek, E.J., Zhang, H., Zha, X.M., Polakiewicz, R.D., and Comb, M.J. (2005). Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. *Nat. Biotechnol.* 23, 94–101.
- Schmid, W., and Fanconi, G. (1978). Fragility and spiralization anomalies of the chromosomes in three cases, including fraternal twins, with Fanconi's anemia, type Estren-Dameshek. *Cytogenet. Cell Genet.* 20, 141–149.
- Silverman, J., Takai, H., Buonomo, S.B., Eisenhaber, F., and de Lange, T. (2004). Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint. *Genes Dev.* 18, 2108–2119.
- Tagwerker, C., Flick, K., Cui, M., Guerrero, C., Dou, Y., Auer, B., Baldi, P., Huang, L., and Kaiser, P. (2006). A tandem affinity tag for two-step purification under fully denaturing conditions: application in ubiquitin profiling and protein complex identification combined with in vivo cross-linking. *Mol. Cell. Proteomics* 5, 737–748.
- Taniguchi, T., and D'Andrea, A.D. (2006). Molecular pathogenesis of Fanconi anemia: recent progress. *Blood* 107, 4223–4233.
- Taniguchi, T., Garcia-Higuera, I., Xu, B., Andreassen, P.R., Gregory, R.C., Kim, S.T., Lane, W.S., Kastan, M.B., and D'Andrea, A.D. (2002). Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. *Cell* 109, 459–472.
- Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., Liu, X., Jasin, M., Couch, F.J., and Livingston, D.M. (2006). Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Mol. Cell* 22, 719–729.
- Xia, B., Dorsman, J.C., Ameziane, N., de Vries, Y., Rooimans, M.A., Sheng, Q., Pals, G., Errami, A., Gluckman, E., Llera, J., et al. (2007). Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. *Nat. Genet.* 39, 159–161.
- Yamamoto, K., Hirano, S., Ishiai, M., Morishima, K., Kitao, H., Nami-koshi, K., Kimura, M., Matsushita, N., Arakawa, H., Buerstedde, J.M., et al. (2005). Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination. *Mol. Cell. Biol.* 25, 34–43.
- Zhou, B.B., and Elledge, S.J. (2000). The DNA damage response: putting checkpoints in perspective. *Nature* 408, 433–439.
- Zou, L., Cortez, D., and Elledge, S.J. (2002). Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. *Genes Dev.* 16, 198–208.

Accession Numbers

The GenBank accession number for *FANCI* is EF469766.